Elements for a Public Summary
|
|
- Gwen Armstrong
- 6 years ago
- Views:
Transcription
1 VI.2 Elements for a Public Summary Fluticasone propionate / formoterol fumarate are available in pressarised metered dose inhalers (pmdi) under the brand names Flutiform, and in breath actuated inhalers under the brand names Flutiform K-Haler, Affera K-Haler, Abriff K-Haler. Within this sumamary these are referred to simply as Flutiform. VI.2.1 Overview of disease epidemiology Asthma, one of the most common chronic diseases in the world, affects around 300 million people worldwide. A recent study found that 4 out of 100 people will have been diagnosed with asthma worldwide. However, the estimates differ across countries and regions, ranging from 2 out of 1000 in China to 2 out of 10 people in Australia and Sweden. Around half of those diagnosed with asthma will have experienced an asthma attack in the past 12 months. The severity of asthma can be classified using a measure of how well the disease is treated and controlled, or the frequency and severity with which symptoms occur. A study looking at patients diagnosed with asthma found that only a third of patients in the UK had their asthma well controlled. VI.2.2 Summary of treatment benefits Overall, 22 clinical studies were conducted in approximately 6,000 patients. 225 of these patients were adolescents. In five 8 to 12-week studies in 2447 patients fluticasone propionate / formoterol fumarate showed better efficacy compared to fluticasone alone with regards to lung function, asthma symptoms, asthma exacerbations and study discontinuations due to lack of efficacy. Three of these studies also showed a better efficacy of compared to formoterol alone. In an 8-week study in 620 patients fluticasone propionate / formoterol fumarate showed comparable efficacy to the combination of fluticasone propionate and formoterol fumarate when administered as separate inhalers with regards to the same measurements. In two further 12- week studies in 481 patients the efficacy and safety of fluticasone propionate / formoterol fumarate was comparable to that of Seretide and Symbicort which are two commonly used medications in asthma. Two studies in 752 patients confirmed the long term efficacy and safety of fluticasone propionate / formoterol fumarate over 6 to 15 months. The rates of asthma exacerbations and discontinuations due to lack of efficacy were very low. Improvements in lung function were sustained over the entire treatment period. In a 12-week study including a 6-month extension phase in 210 children aged 4 to 12 years Fluticasone propionate / formoterol fumarate showed comparable efficacy and safety to Seretide. 205 patients completed the 6-month extension phase during which fluticasone propionate / formoterol fumarate was safe and well tolerated. An additional comparative study included a further 274 children aged 5 to 12 years providing further support that fluticasone propionate / formoterol fumarate was safe and well tolerated. VI.2.3 Unknowns relating to treatment benefits In studies most patients were white, aged between 4 and 81 and suffering from mild to severe asthma. It is unlikely that results would be different in non-white patients. No information is available for use in patients with liver or kidney disease. RMP Fluticasone propionate/formoterol fumarate breath-actuated inhaler Version 4.0, 29 Sep
2 VI.2.4 Summary of safety concerns Important identified risks Part VI. Table 3 Summary of safety concerns Important identified risks Risk What is known Preventability An irregular heart beat (cardiac arrhythmias) Problems with the blood flow to your heart (Cardiac ischaemia / ischemic heart disease, IHD) Increase in the amount of sugar in the blood (hyperglycaemia) Asthma exacerbations are expected under treatment with fluticasone propionate / formoterol fumarate inhaler (Flutiform) since this medication is used in asthma and some patients may experience worsening of their asthma. Sleeping problems, depression or feeling worried, aggression, anxiety, restlessness, nervousness, overexcitment or irritability (psychological or behavioural effects). The term cardiac arrhythmia covers a very large number of very different conditions. Most arrhythmias are harmless, but some can be serious or even life threatening. Patients with underlying history of cardiovascular disease are an identified risk group. Probably less than 1 in 100 people using this inhaler experienced an irregular heartbeat or palpitations. And probably less than 1 in 1000 people using this inhaler are affected by fast heartbeat followingg use of this inhaler. Ischemic heart disease or myocardial ischaemia is potentially lifethreatening. Patients with underlying history of ischaemic heart disease are an identified risk group. Probably less than 1 in 1000 people using this inhaler are affected by chest pain associated with heart disease. Patients with underlying history of diabetes mellitus are an identified risk group. An increase in the amount of sugar in the blood affects probably less than 1 in 100 people using this inhaler. Probably less than 1 in 100 people using this inhaler experience worsening of asthma. Some psychological and behavioural effects have been associated with use of the steroid component fluticasone propionate in fluticasone propionate / formoterol fumarate inhaler. These have not been reported with Flutiform and the frequency these effects occur with is not known. These effects are more likely to occur in children. Yes: before treatment with this inhaler tell your doctor, pharmacist or asthma nurse if you have an irregular heart beat (cardiac arrhythmia) Yes: before treatment with this inhaler tell your doctor, pharmacist or asthma nurse if you have problems with the blood flow to your heart Yes: before treatment with this inhaler tell your doctor, pharmacist or asthma nurse if you have diabetes. If you are diabetic you may need to check your blood sugar more often and adjust your usual diabetic treatment. Your doctor may need to monitor you more closely. Yes: It is advised that you should use this medicine every day as directed by your doctor or asthma nurse. This medicine helps to prevent breathing problems such as asthma and helps to stop you becoming breathless and wheezy. However, it does not work if you are already having an asthma attack i.e. you are already breathless and wheezing. You will need to use a fast acting reliever medicine such as salbutamol if this happens. Yes, adhere to the guidance provided in the patient information leaflet for Flutiform inhaler, especially sections 3. How to use Flutiform inhaler and 4. Possible side effects. If any of the side effects become serious, or if you notice any other side effects affecting your behaviour or mood not listed in the patient information leaflet, please RMP Fluticasone propionate/formoterol fumarate breath-actuated inhaler Version 4.0, 29 Sep
3 tell your doctor, pharmacist or asthma nurse. Important potential risks Part VI. Table 4 Summary of safety concerns Important potential risks Risk What is known (including reason why it is considered a potential risk) Allergic reactions with characteristic All medicines can cause allergic reactions, although serious symptoms of sudden swelling of the allergic reactions are reported rarely. Some drugs may cause eyelids, face, throat, tongue or lips, rash allergic reactions when people are first exposed to them. or itching especially those covering the whole body, symptoms such as dizziness, light-headedness or fainting or any sudden changes in breathing pattern such as increased wheezing or shortness of breath Poor adrenal gland function (adrenal suppression) Slowing of the rate of growth of children and adolescents (growth retardation) Changes in bone mineral density with thinning of the bones (decrease in bone mineral density) An abnormal heart trace potentially leading to an abnormal heart rhythm (QTc interval prolongation) Serious asthma- related events with severe breathlessness and wheezing. Constriction of the airways after treatment with a bronchodilator (paradoxical bronchospasm) Clouding of the lens in the eye (cataract) Increased pressure in the eye (glaucoma) Decrease in the amount of potassium in the blood (hypokalaemia) developing decreased adrenal gland function. Poor adrenal gland function means that your adrenal gland is not working properly and you may have symptoms such as headaches, weakness, tiredness, abdominal pain, loss of appetite, weight loss, dizziness, very low blood pressure, diarrhoea, feeling or being sick or fits. Flutiform inhaler contains a steroid. Children and adolescents treated with steroids may be at an increased risk of slowing of the rate of their growth. Flutiform inhaler contains a steroid. This risk is more likely to occur after oral use of steroids or prolonged high doses. developing changes in bone mineral density with thinning of the bones which means having a higher risk for fractures. Flutiform inhaler contains a steroid. The risk is more likely to occur after oral use of steroids or prolonged high doses. Patients treated with ß- agonists such as formoterol are at an increased risk of developing an abnormal heart trace potentially leading to an abnormal heart rhythm. Flutiform inhaler contains a ß- agonist (formoterol). Since Flutiform inhaler is used in asthma some patients may experience a severe worsening of their asthma. These events can be potentially life threatening and require immediate medical consultation and therapy. Paradoxical bronchospasm with an immediate increase in wheezing and shortness of breath after dosing has been reported with other asthma inhalation products. developing clouding of the lens in the eye. Flutiform inhaler contains a steroid. The risk is more likely to occur after oral use of steroids or prolonged high doses. developing increased pressure in the eye. Flutiform inhaler contains a steroid. The risk is more likely to occur after oral use of steroids or prolonged high doses. Patients treated with ß- agonists such as formoterol are at an increased risk of developing decrease in the amount of potassium in the blood which can cause muscle weakness, RMP Fluticasone propionate/formoterol fumarate breath-actuated inhaler Version 4.0, 29 Sep
4 Use of fluticasone propionate / formoterol fumarate inhaler (Flutiform) in other indications such as chronic obstructive lung disease, younger children or for acute asthma attacks (Off-label use) twitching or abnormal heart rhythm. Flutiform inhaler contains a ß- agonist (formoterol). Children below 5 years should not use Flutiform inhaler as there is limited data on the safety of use in children. Currently Flutiform inhaler is not approved for use in children aged 5 to 12 years of age. The same applies to patients suffering from chronic obstructive lung disease. Flutiform inhaler should further not be used as treatment of acute asthma attacks (reliever treatment). Missing information Part VI. Table 5 Summary of safety concerns Missing information Risk What is known Limited information on use in patients with liver impairment Limited information on use in patients with kidney impairment Current smoking history Long-term safety and efficacy of the new combination of fluticasone and HFA 227 (propellant) The use of Flutiform inhaler in subjects with liver impairment has not been investigated during its clinical development programme. Such patients should be regularly monitored. The use of Flutiform inhaler in subjects with kidney impairment has not been investigated during its clinical development programme. Such patients should be regularly monitored. Smokers may require higher doses of steroids to achieve the same effect of the asthma treatment than non- smokers. The use of Flutiform inhaler in smokers has not been investigated during its clinical development programme. Flutiform inhaler is the first asthma inhaler product using the propellant component HFA227 together with the corticosteroid fluticasone. VI.2.4 Summary of risk minimisation measures by safety concern All medicines have a Summary of Product Characteristics (SmPC) which provides physicians, pharmacists and other health care professionals with details on how to use the medicine, the risks and recommendations for minimising them. An abbreviated version of this in lay language is provided in the form of the package leaflet (PL). The measures in these documents are known as routine risk minimisation measures. The Summary of Product Characteristics and the Package leaflet for Flutiform can be found on the Flutiform EPAR page, and for Flutiform K-Haler in the Flutiform K-Haler EPAR page, on the EMA website. There are no additional risk minimisation measures. RMP Fluticasone propionate/formoterol fumarate breath-actuated inhaler Version 4.0, 29 Sep
5 VI.2.5 Planned post authorisation development plan Part VI. Table 7 List of studies in post authorisation development plan Study/ activity Objectives Safety concerns addressed Status PASS: FLT9501 Title: Flutiform a new combination in the treatment of asthma in real life setting. Noninterventional study on safety and effectiveness Short title: ffairness Primary objectives: Safety and effectiveness of Flutiform [fluticasone propionate / formoterol fumarate] prescribed for outpatients aged 12 years with asthma: Evaluation of the safety and effectiveness (efficacy under real life conditions) of fluticasone propionate / formoterol fumarate in routine clinical practice by Collection of data on the exposure to Flutiform [fluticasone propionate / formoterol fumarate] and evaluation of asthma control and the frequency of adverse events associated with Flutiform [fluticasone propionate / formoterol fumarate], or which are known to be side effects of treatment with ICS/LABA combination drugs. All adverse events reported spontaneously or after physicians open question by the patients as well as adverse events detected by diagnostic procedures during routine clinical practice at the physicians discretion will be recorded. The primary efficacy parameter will be asthma control under therapy with Flutiform [fluticasone propionate / formoterol fumarate], assessed by comparing the ACTTM, total score, between baseline and end of study. Secondary objectives: Secondary objectives are to evaluate the effectiveness of Flutiform [fluticasone propionate / formoterol fumarate] treatment on asthma control by further parameters (e.g. daytime/nighttime symptoms, exacerbation rate, use of asthma related rescue medication) and by lung function parameters. In addition, the NIS shall provide deeper insights in the course of the therapy with Flutiform [fluticasone propionate / formoterol fumarate] over one year with regard to dose adjustments, changes in asthma-related co-medication and discontinuation due to lack of efficacy as well as the patients and the physicians satisfaction with the Flutiform [fluticasone propionate / formoterol fumarate]therapy. All important identified and potential risks and missing information Current smoking history and Long-term safety and efficacy of the new combination of fluticasone and HFA 227 (propellant). Ongoing Date for submission of interim or final reports Submission of data within 6 months after LPLV. (Q2 2016). RMP Fluticasone propionate/formoterol fumarate breath-actuated inhaler Version 4.0, 29 Sep
6 Study/ activity Objectives Safety concerns addressed Status PASS: FLT9503 Title: A Non interventional post authorisation study to determine the safety and effectiveness of Flutiform (Affirm Study). Short title Assessment of fluticasone/ formoterol In Real life Maintenance treatment (Affirm). Primary objectives: Evaluation of the safety of Flutiform in routine clinical practice by Collection of data on the exposure to Flutiform and the frequency of adverse events associated with Flutiform, or which are known to be side effects of treatment with ICS/LABA combination drugs. Recording all adverse events reported spontaneously or after physicians open question by the subjects as well as adverse events detected by diagnostic procedures during routine clinical practice at the physicians discretion. Secondary objectives: Secondary objectives are to evaluate the effectiveness of Flutiform treatment under real life conditions on asthma control by comparing the Asthma Control Test (ACTTM) total score between baseline and end of study and further parameters (e.g. exacerbation rate, use of asthma related rescue medication, asthma symptoms and sleep disturbance from the ACT sub scores, consultations and hospitalisations due to asthma, days of absence from work/school/college or inability to perform everyday activities due to asthma) and by lung function parameters. In addition, the study shall provide deeper insights in the course of the therapy with Flutiform over one year with regard to dose adjustments, changes in asthma-related co-medication and discontinuation due to lack of efficacy as well as the subjects and the physicians satisfaction with the Flutiform therapy. All important identified and potential risks and missing information Current smoking history and Long-term safety and efficacy of the new combination of fluticasone and HFA 227 (propellant). Finished recruiting Date for submission of interim or final reports 30SEP2016 RMP Fluticasone propionate/formoterol fumarate breath-actuated inhaler Version 4.0, 29 Sep
7 Study/ activity Objectives Safety concerns addressed Status Evaluation of realworld prescribing of fixed-dose combination inhaled corticosteroid / long-acting ß2- agonist (ICS/LABA) fluticasone propionate / formoterol (FP/FOR) and adverse events in routine primary care Sub-title: Characterisation of real-world FP/FOR prescribing and adverse events [CPRD study] (1) To characterise real-world prescribing of FP/FOR [fluticasone propionate / formoterol fumarate] as used in clinical practice and to identify and quantify prevalence of off-label prescribing. (2) To evaluate the adverse event rates in patients prescribed FP/FOR on and off label (3) To compare adverse event rates in patients prescribed FP/FOR on and off label with rates in appropriate matched controls. All important identified and potential risks and missing information Off-label use and Long-term safety and efficacy of the new combination of fluticasone and HFA 227 (propellant). Date for submission of interim or final reports Ongoing Final Q RMP Fluticasone propionate/formoterol fumarate breath-actuated inhaler Version 4.0, 29 Sep
Summary of the risk management plan (RMP) for Budesonide/Formoterol Teva (budesonide / formoterol)
EMA/639304/2014 Summary of the risk management plan (RMP) for Budesonide/Formoterol Teva (budesonide / formoterol) This is a summary of the risk management plan (RMP) for Budesonide/Formoterol Teva, which
More informationSummary of the risk management plan (RMP) for Vylaer Spiromax (budesonide / formoterol)
EMA/675937/2014 Summary of the risk management plan (RMP) for Vylaer Spiromax (budesonide / formoterol) This is a summary of the risk management plan (RMP) for Vylaer Spiromax, which details the measures
More informationSummary of the risk management plan (RMP) for DuoResp Spiromax (budesonide / formoterol)
EMA/126654/2014 Summary of the risk management plan (RMP) for DuoResp Spiromax (budesonide / formoterol) This is a summary of the risk management plan (RMP) for DuoResp Spiromax, which details the measures
More informationSummary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate)
EMA/605453/2014 Summary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate) This is a summary of the risk management plan (RMP) for Duaklir Genuair, which
More information7.2 Part VI.2 Elements for a Public Summary
7.2 Part VI.2 Elements for a Public Summary 7.2.1 Part VI.2.1 Overview of disease epidemiology Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Flutiform 50 microgram /5 microgram, 125 microgram /5 microgram and 250 microgram /10 microgram per actuation pressurised inhalation, suspension fluticasone propionate/formoterol
More informationSummary of the risk management plan (RMP) for Nucala (mepolizumab)
EMA/671186/2015 Summary of the risk management plan (RMP) for Nucala (mepolizumab) This is a summary of the risk management plan (RMP) for Nucala, which details the measures to be taken in order to ensure
More informationSummary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol)
EMA/258177/2014 Summary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol) This is a summary of the risk management plan (RMP) for Laventair, which details the measures
More informationOXEZE TURBUHALER formoterol fumarate dihydrate dry powder for oral inhalation
IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION OEZE TURBUHALER formoterol fumarate dihydrate dry powder for oral inhalation This leaflet is part III of a three-part Product Monograph published when
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Turbohaler budesonide. 1. What Pulmicort Turbohaler is and what it is used for
PACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Turbohaler budesonide Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again. If
More informationPackage leaflet: Information for the user. Seretide Accuhaler
Package leaflet: Information for the user Seretide Accuhaler 50 microgram /100 microgram /dose inhalation powder, pre-dispensed. 50 microgram /250 microgram /dose inhalation powder, pre-dispensed. 50 microgram
More informationOXEZE TURBUHALER formoterol fumarate dihydrate
IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION OEZE TURBUHALER formoterol fumarate dihydrate This leaflet is part III of a three-part Product Monograph published when OEZE TURBUHALER was approved
More informationScan this code or visit xxxx [to be completed nationally] to see instructions on how to use Easyhaler
QR code to www.oeh.fi/ xxxx [to be completed nationally]. Scan this code or visit www.oeh.fi/ xxxx [to be completed nationally] to see instructions on how to use Easyhaler Package leaflet: Information
More informationMEDICATION GUIDE. ADVAIR [ad vair] HFA 45/21 (fluticasone propionate 45 mcg and salmeterol 21 mcg) Inhalation Aerosol
MEDICATION GUIDE ADVAIR [ad vair] HFA 45/21 (fluticasone propionate 45 mcg and salmeterol 21 mcg) Inhalation Aerosol ADVAIR HFA 115/21 (fluticasone propionate 115 mcg and salmeterol 21 mcg) Inhalation
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Salmex 50 microgram /100 microgram /dose inhalation powder, pre-dispensed. Salmex 50 microgram /250 microgram /dose inhalation powder, pre-dispensed. Salmex 50
More informationSwiss Summary of the Risk Management Plan (RMP) for Nucala (Mepolizumab)
Swiss Summary of the Risk Management Plan (RMP) for Nucala (Mepolizumab) RMP Summary: Version 1, March 2017 EU RMP: Version 2, 26.5.2016 The Risk Management Plan (RMP) is a comprehensive document submitted
More informationPackage leaflet: Information for the user. Seretide Evohaler
Allen & Hanburys Package leaflet: Information for the user Seretide Evohaler 25 microgram/50 microgram/dose pressurised inhalation, suspension 25 microgram/125 microgram/dose pressurised inhalation, suspension
More informationRexair Inhaler Consumer Medicine Information
Rexair Inhaler Consumer Medicine Information Fluticasone Propionate and Salmeterol (as xinafoate) 50 mcg/25 mcg, 125 mcg/25 mcg, 250 mcg/25 mcg suspension for inhalation 120 ACTUATIONS What is in this
More informationSummary of the risk management plan (RMP) for Ivabradine Anpharm (ivabradine)
EMA/518024/2015 Summary of the risk management plan (RMP) for Ivabradine Anpharm (ivabradine) This is a summary of the risk management plan (RMP) for Ivabradine Anpharm, which details the measures to be
More informationyour breathing problems worsen quickly. you use your rescue inhaler, but it does not relieve your breathing problems.
MEDICATION GUIDE ADVAIR DISKUS [ad vair disk us] (fluticasone propionate and salmeterol inhalation powder) for oral inhalation What is the most important information I should know about ADVAIR DISKUS?
More informationDULERA [dew-lair-ah] 100 mcg/5 mcg DULERA 200 mcg/5 mcg What is DULERA? DULERA is not used to relieve sudden breathing problems Do not use DULERA:
PATIENT INFORMATION DULERA [dew-lair-ah] 100 mcg/5 mcg (mometasone furoate 100 mcg and formoterol fumarate dihydrate 5 mcg) Inhalation Aerosol DULERA 200 mcg/5 mcg (mometasone furoate 200 mcg and formoterol
More informationSummary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin)
EMA/247834/2014 Summary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin) Overview of disease epidemiology Epilepsy Epilepsy is a long-term condition affecting the brain and is characterised
More informationSummary of the risk management plan (RMP) for Duloxetine Mylan (duloxetine)
EMA/281284/2015 Summary of the risk management plan (RMP) for Duloxetine Mylan (duloxetine) This is a summary of the risk management plan (RMP) for Duloxetine Mylan, which details the measures to be taken
More informationPackage leaflet: Information for the patient. Icsori 250 microgram per actuation pressurised inhalation, suspension. fluticasone propionate
Package leaflet: Information for the patient Icsori 125 microgram per actuation pressurised inhalation, suspension Icsori 250 microgram per actuation pressurised inhalation, suspension fluticasone propionate
More informationSummary of the risk management plan (RMP) for Kengrexal (cangrelor)
EMA/78859/2015 Summary of the risk management plan (RMP) for Kengrexal (cangrelor) This is a summary of the risk management plan (RMP) for Kengrexal, which details the measures to be taken in order to
More informationOXIS TURBUHALER Formoterol fumarate dihydrate for inhalation
OXIS TURBUHALER Formoterol fumarate dihydrate for inhalation Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Oxis Turbuhaler. It does not contain
More informationSummary of the risk management plan (RMP) for Pregabalin Mylan (pregabalin)
EMA/285074/2015 Summary of the risk management plan (RMP) for Pregabalin Mylan (pregabalin) This is a summary of the risk management plan (RMP) for Pregabalin Mylan, which details the measures to be taken
More informationSummary of safety concerns Important identified risks
Valley VI.2 Elements for a public summary NL/H/3661/001-002/DC - Ivabradin Medical VI.2.1 Overview of disease epidemiology Ivabradine is a medicine used for two long-term (chronic) heart conditions: to
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) MODAFINIL ORION 100 MG, 200 MG Tablets ORION CORPORATION DATE: , VERSION 1.
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) MODAFINIL ORION 100 MG, 200 MG Tablets ORION CORPORATION DATE: 22-04-2015, VERSION 1.1 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology
More informationSummary of the risk management plan (RMP) for Duloxetine Zentiva (duloxetine)
EMA/450483/2015 Summary of the risk management plan (RMP) for Duloxetine Zentiva (duloxetine) This is a summary of the risk management plan (RMP) for Duloxetine Zentiva, which details the measures to be
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Symbicort Turbohaler 400/12, inhalation powder budesonide, formoterol fumarate dihydrate
PACKAGE LEAFLET: INFORMATION FOR THE USER Symbicort Turbohaler 400/12, inhalation powder budesonide, formoterol fumarate dihydrate Read all of this leaflet carefully before you start taking this medicine.
More informationEasyhaler Beclometasone 200 micrograms/dose inhalation powder
Package Leaflet: Information for the user Easyhaler Beclometasone 200 micrograms/dose inhalation powder Beclometasone dipropionate Read all of this leaflet carefully before you start using this medicine
More informationSummary of the risk management plan (RMP) for Duloxetine Lilly (duloxetine)
EMA/674705/2014 Summary of the risk management plan (RMP) for Duloxetine Lilly (duloxetine) This is a summary of the risk management plan (RMP) for Duloxetine Lilly which details the measures to be taken
More informationPackage leaflet: Information for the user. Qvar 50 & 100 aerosol Beclometasone Dipropionate
Package leaflet: Information for the user Qvar 50 & 100 aerosol Beclometasone Dipropionate Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationAIRFLUSAL FORSPIRO 50 µg/500 µg Inhalation powder, pre-dispensed
PACKAGE LEAFLET: INFORMATION FOR THE USER AIRFLUSAL FORSPIRO 50 µg/500 µg Inhalation powder, pre-dispensed SALMETEROL/ FLUTICASONE PROPIONATE This leaflet is a copy of the Summary of Product Characteristics
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Respules 1 mg/2 ml Nebuliser Suspension budesonide
PACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Respules 1 mg/2 ml Nebuliser Suspension budesonide Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may
More informationPackage leaflet: Information for the patient. Sirdupla
Package leaflet: Information for the patient Sirdupla 25 microgram/125 microgram per metered dose pressurised inhalation, suspension 25 microgram/250 microgram per metered dose pressurised inhalation,
More informationPatient Information ALVESCO [ael- ves-koʊ] (ciclesonide) Inhalation Aerosol. Do not use your ALVESCO Inhalation Aerosol near heat or an open flame.
Note: For Oral Inhalation Only Patient Information ALVESCO [ael- ves-koʊ] (ciclesonide) Inhalation Aerosol Do not use your ALVESCO Inhalation Aerosol near heat or an open flame. Read this Patient Information
More informationVentamol CFC-Free 100 micrograms, Pressurised Inhalation, Suspension (Salbutamol)
Ventamol CFC-Free 100 micrograms, Pressurised Inhalation, Suspension (Salbutamol) For inhalation use Important: Read instructions carefully Wash your inhaler once a week and allow to dry What you need
More informationNEW ZEALAND CONSUMER MEDICINE INFORMATION. Salbutamol (as sulfate) 100 micrograms per actuation inhalation aerosol
NEW ZEALAND CONSUMER MEDICINE INFORMATION RESPIGEN TM Salbutamol (as sulfate) 100 micrograms per actuation inhalation aerosol Read all of this leaflet carefully before you start using this medicine. Keep
More informationSerevent Diskus 50 microgram per metered dose inhalation powder, pre-dispensed
Agency Approval Date: Not applicable as IA Text Date: 27 April 2015 CO-0111149 GSK Logo Package Leaflet: Information for the User Serevent Diskus 50 microgram per metered dose inhalation powder, pre-dispensed
More informationSummary of the risk management plan (RMP) for Kyprolis (carfilzomib)
EMA/639793/2015 Summary of the risk management plan (RMP) for Kyprolis (carfilzomib) This is a summary of the risk management plan (RMP) for Kyprolis, which details the measures to be taken in order to
More informationPackage leaflet: Information for the user Pulmicort Respules 0.5 mg, Nebuliser Suspension budesonide
Package leaflet: Information for the user Pulmicort Respules 0.5 mg, Nebuliser Suspension budesonide Read all of this leaflet carefully before you start using this medicine because it contains important
More informationElements for a public summary
VI.2 Elements for a public summary Part VI.2 Elements for a public summary is applicable for all products that are covered by this RMP, except from the important potential risk of Medication error with
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Qvar Easi-Breathe 50 micrograms per actuation Inhaler Qvar Easi-Breathe 100 micrograms per actuation Inhaler Beclometasone Dipropionate Read all of this leaflet
More informationSwiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide)
Swiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide) RMP Summary: Version 1, November 2017 EU RMP: Version 1.0, November 2016 Page 1 of 6 The Risk Management Plan (RMP) is a comprehensive
More informationSERETIDE Fluticasone propionate/salmeterol xinafoate
SERETIDE Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information What is in this leaflet Please read this leaflet carefully before you start using Seretide. This leaflet answers some
More informationPlease read this leaflet carefully before you start using Fluticasone Cipla Inhaler.
Inhaler 125 microgram and 250 microgram MDI Fluticasone propionate Consumer Medicine Information Please read this leaflet carefully before you start using Inhaler. What is in this leaflet This leaflet
More informationSERETIDE Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information
SERETIDE Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information What is in this leaflet Please read this leaflet carefully before you start using Seretide. This leaflet answers some
More informationVentolin Accuhaler 200 micrograms salbutamol sulfate
Package Leaflet: Information for the User Ventolin Accuhaler 200 micrograms salbutamol sulfate Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationFLIXOTIDE CFC-FREE INHALER and JUNIOR CFC-FREE INHALER ['PUFFER'] Fluticasone propionate Consumer Medicine Information
FLIXOTIDE CFC-FREE INHALER and JUNIOR CFC-FREE INHALER ['PUFFER'] Fluticasone propionate Consumer Medicine Information Please read this leaflet carefully before you start using Flixotide (CFC-free) Inhaler.
More informationScan this code or visit to see instructions on how to use Easyhaler. Package leaflet: Information for the patient
QR code to www.oeh.fi/bfgb Scan this code or visit http://www.oeh.fi/bfgb to see instructions on how to use Easyhaler Package leaflet: Information for the patient Fobumix Easyhaler 160 micrograms/ 4.5
More informationSummary of the risk management plan (RMP) for Omidria (phenylephrine / ketorolac)
EMA/368070/2015 Summary of the risk management plan (RMP) for Omidria (phenylephrine / ketorolac) This is a summary of the risk management plan (RMP) for Omidria, which details the measures to be taken
More informationPackage Leaflet Information for the user Fostair 100/6 micrograms per actuation pressurised inhalation solution
Package Leaflet Information for the user Fostair 100/6 micrograms per actuation pressurised inhalation solution beclometasone dipropionate/ formoterol fumarate dihydrate. For use in adults. Read all of
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Bufar Easyhaler, 320 micrograms/9 micrograms/inhalation, Inhalation Powder Budesonide/formoterol fumarate dihydrate Read all of this leaflet carefully before
More informationPATIENT INFORMATION. ADVAIR DISKUS [AD vair DISK us] (fluticasone propionate and salmeterol inhalation powder) for oral inhalation
PATIENT INFORMATION ADVAIR DISKUS [AD vair DISK us] (fluticasone propionate and salmeterol inhalation powder) for oral inhalation What is ADVAIR DISKUS? ADVAIR DISKUS combines the inhaled corticosteroid
More informationDo not use Easyhaler Salbutamol if you are allergic (hypersensitive) to: Salbutamol lactose
Package leaflet: Information for the patient user Easyhaler Salbutamol Sulphate 100 and 200 micrograms/dose inhalation powder Salbutamol sulphate (salbutamol) Read all of this leaflet carefully before
More informationONBREZ BREEZHALER should only be used to treat COPD.
CONSUMER INFORMATION Pr ONBREZ BREEZHALER Indacaterol maleate This leaflet is part III of a three-part "Product Monograph" published when ONBREZ BREEZHALER was approved for sale in Canada and is designed
More informationRisk Management Plan Summary
Risk Management Plan Summary TREMFYA (guselkumab) 100 mg/ml pre-filled syringe Document Version: 1.0 (11.07.2018) Based on EU RMP version 1.2 Marketing authorization holder: Janssen-Cilag AG, Gubelstr.
More informationSummary of the risk management plan (RMP) for Gazyvaro (obinutuzumab)
EMA/319729/2014 Summary of the risk management plan (RMP) for Gazyvaro (obinutuzumab) This is a summary of the risk management plan (RMP) for Gazyvaro, which details the measures to be taken in order to
More informationBeclazone 50, 100, 250 micrograms CFC-Free Inhaler
NEW ZEALAND CONSUMER MEDICINE INFORMATION Beclazone 50, 100, 250 micrograms CFC-Free Inhaler Beclometasone dipropionate 50, 100, or 250 micrograms per metered dose ( puff ) Please read this leaflet carefully
More informationOlmesartan is used for treating high blood pressure (hypertension) in adult patients.
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Olmesartan is used for treating high blood pressure (hypertension) in adult patients. Essential hypertension 1 Worldwide, it is
More informationPATIENT INFORMATION LEAFLET BILOCOR RANGE
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM BILOCOR 5 tablets BILOCOR 10 tablets Please read this leaflet carefully before using BILOCOR 5 / 10 mg tablets Keep this leaflet.
More informationSummary of Treatment Benefits Page 72 of 111. Page 72
1.8.2 Page 72 of 111 Page 72 need surgery to remove part or all of the thyroid gland. This procedure is known as a thyroidectomy (removal of thyroid gland), and is followed by life-long intake of levothyroxine.
More informationSummary of the risk management plan (RMP) for Ketoconazole HRA (ketoconazole)
EMA/609213/2014 Summary of the risk management plan (RMP) for Ketoconazole HRA (ketoconazole) This is a summary of the risk management plan (RMP) for Ketoconazole HRA, which details the measures to be
More information1 What Flixotide is and what it is used for
GSK Logo Package Leaflet: Information for the user Flixotide Diskus 50 micrograms, 100 micrograms, 250 micrograms, 500 micrograms Inhalation Powder, pre-dispensed (fluticasone propionate) Read all of this
More informationA study conducted in Norway found the combined estimate for panic and generalized anxiety disorder was 1.10 per 1,000 person-years.
VI.2 Elements for a public summary For sake of completeness, with reference to article 11 of the Directive 2001/83, the applicant retains the option to carve out the patented indication in the national
More informationSYMBICORT TURBUHALER Budesonide and formoterol (eformoterol) fumarate dihydrate powder for inhalation
SYMBICORT TURBUHALER Budesonide and formoterol (eformoterol) fumarate dihydrate powder for inhalation Consumer Medicine Information What is in this leaflet? This leaflet answers some common questions about
More informationSummary of the risk management plan (RMP) for Moventig (naloxegol)
EMA/611606/2014 Summary of the risk management plan (RMP) for Moventig (naloxegol) This is a summary of the risk management plan (RMP) for Moventig, which details the measures to be taken in order to ensure
More informationPackage leaflet: Information for the user. Seretide Accuhaler
Package leaflet: Information for the user Seretide Accuhaler 50 microgram /100 microgram /dose inhalation powder, pre-dispensed. 50 microgram /250 microgram /dose inhalation powder, pre-dispensed. 50 microgram
More informationSYMBICORT TURBUHALER
Budesonide and formoterol (eformoterol) fumarate dihydrate powder for inhalation Consumer Medicine Information What is in this leaflet? This leaflet answers some common questions about Symbicort Turbuhaler.
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Flixotide 50 micrograms Evohaler fluticasone propionate Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Schizophrenia Schizophrenia is a mental illness with a number of symptoms, including confused or unclear thinking and speech,
More informationRISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.
RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion
More informationPackage leaflet: Information for the patient. Duohal 25 micrograms /125 micrograms /dose pressurised inhalation, suspension
Package leaflet: Information for the patient Duohal 25 micrograms /125 micrograms /dose pressurised inhalation, suspension Duohal 25 micrograms /250 micrograms /dose pressurised inhalation, suspension
More informationDiseases in which appear swelling, redness, pain and heat; aspects of the immune system (Inflammatory and immunologic conditions-imid)
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Prednisolone is generally preferred amongst glucocorticoids for anti-inflammatory and immunosuppressive treatment. There are three
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CIPROFLOXACIN ORION 750 MG FILM-COATED TABLETS ORION OYJ DATE: , VERSION 1.
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CIPROFLOXACIN ORION 250 MG FILM-COATED TABLETS CIPROFLOXACIN ORION 500 MG FILM-COATED TABLETS CIPROFLOXACIN ORION 750 MG FILM-COATED TABLETS ORION OYJ DATE:
More informationPregabalin Aristo Version: RMP-Pregabalin0
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Epilepsy Epilepsy is a long-term condition affecting the brain and is characterised by recurring seizures (or fits). It is one
More informationSummary of the risk management plan (RMP) for Vizamyl (flutemetamol 18 F)
EMA/404996/2014 Summary of the risk management plan (RMP) for Vizamyl (flutemetamol 18 F) This is a summary of the risk management plan (RMP) for Vizamyl, which details the measures to be taken in order
More informationRisk Management Plan Summary
Risk Management Plan Summary EDURANT (rilpivirine) 25 mg film-coated tablet Document Version: 1.0 Document Date: 30.10.2017 Based on EU RMP version 7.0 Marketing authorization holder: Janssen-Cilag AG,
More information1 What Seretide is and what it is used for
Package leaflet: Information for the user Seretide Evohaler 25 microgram/50 microgram per metered dose pressurised inhalation, suspension 25 microgram/125 microgram per metered dose pressurised inhalation,
More informationSummary of the risk management plan (RMP) for Nivolumab BMS (nivolumab)
EMA/359171/2015 Summary of the risk management plan (RMP) for Nivolumab BMS (nivolumab) This is a summary of the risk management plan (RMP) for Nivolumab BMS, which details the measures to be taken in
More informationSeretide MDI contains two medicines, fluticasone propionate and salmeterol xinafoate.
SERETIDE MDI Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information What is in this leaflet? Please read this leaflet carefully before you use Seretide MDI. This leaflet answers some
More informationSERETIDE MDI (with counter)
. SERETIDE MDI (with counter) Fluticasone propionate/salmeterol xinafoate Consumer Medicine Information What is in this leaflet? Please read this leaflet carefully before you use Seretide MDI. This leaflet
More informationSummary of the risk management plan (RMP) for Portrazza (necitumumab)
EMA/33513/2016 Summary of the risk management plan (RMP) for Portrazza (necitumumab) This is a summary of the risk management plan (RMP) for Portrazza, which details the measures to be taken in order to
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Symbicort forte Turbuhaler 320 micrograms/9 micrograms/inhalation, Inhalation Powder Budesonide/Formoterol fumarate dihydrate Read all of this leaflet carefully
More informationSummary of the risk management plan (RMP) for Opdivo (nivolumab)
EMA/285771/2015 Summary of the risk management plan (RMP) for Opdivo (nivolumab) This is a summary of the risk management plan (RMP) for Opdivo, which details the measures to be taken in order to ensure
More informationOverview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Acne vulgaris (or simply acne) is a common human skin disease, characterized by areas of skin with seborrhea (scaly red skin),
More informationVENTOLIN. About your Ventolin Respirator Solution. Read all of this leaflet carefully before you use your medicine
Patient Information VENTOLIN About your Ventolin Respirator Solution Read all of this leaflet carefully before you use your medicine This leaflet does not have the complete information about your medicine.
More informationFLUTIFORM inhaler Fluticasone propionate/eformoterol fumarate dihydrate Consumer Medicine Information
FLUTIFORM inhaler Fluticasone propionate/eformoterol fumarate dihydrate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about FLUTIFORM pressurised inhalation
More informationSummary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole)
EMA/370707/2016 Summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma, which details the
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. APO-SALVENT CFC FREE salbutamol sulphate inhalation aerosol
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION APO-SALVENT CFC FREE salbutamol sulphate inhalation aerosol Read this carefully before you start taking APO-SALVENT
More information